Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Department of Neurology and Stroke Unit of Avezzano-Sulmona, ASL 1 Avezzano-Sulmona-L'Aquila, L'Aquila, Italy.
Int J Stroke. 2024 Jun;19(5):515-525. doi: 10.1177/17474930231218594. Epub 2023 Dec 24.
Recent years have seen a change in the use of anticoagulants in the general population due to the availability of direct oral anticoagulants (DOACs) as an alternative to vitamin K antagonists (VKAs) and increased detection of atrial fibrillation. It is important to have updated epidemiological data to understand how this change is impacting on the occurrence and outcome of intracerebral hemorrhage (ICH).
Our prospective population-based registry included patients with first-ever ICH occurring from January 2011 to December 2020. Oral anticoagulants (OAC)-related ICH was defined as an ICH occurring within 48 h from the intake of DOAC or VKAs, regardless of the measured international normalized ratio on hospital admission.
We included 748 first-ever ICH, of whom 108 (14.4%) were OAC-related. Specifically, 75 (69.4%) ICHs occurred on VKA and 33 (30.6%) on DOAC. The incidence of oral anticoagulation-associated intracerebral hemorrhage (OAC-ICH) was stable over time (p = 0.226). Among OAC-ICHs, we observed an increase in the overall incidence of DOAC-ICH (p for trend < 0.001) which overcome that of VKA-ICH in 2020 (incidence rate ratio (IRR) 4.71, 95% confidence interval (CI): 1.22-33.54; p = 0.022). Patients with OAC-ICH showed higher 30-day case fatality rates than those with non-OAC-ICH (48.1% vs 34.1%; p = 0.007).
No changes over time were detected in the incidence of OAC-ICH, but throughout the study period, there was a change in OAC-ICH from mostly VKA-related to mostly DOAC-related. Mortality in patients with OAC-ICH was higher than in patients with non-OAC-ICH.
近年来,由于直接口服抗凝剂(DOACs)作为维生素 K 拮抗剂(VKAs)的替代品的出现以及心房颤动的检出率增加,普通人群中抗凝剂的使用发生了变化。了解这种变化如何影响脑出血(ICH)的发生和结局,获得最新的流行病学数据非常重要。
我们的前瞻性基于人群的登记研究包括 2011 年 1 月至 2020 年 12 月期间首次发生的 ICH 患者。口服抗凝剂(OAC)相关 ICH 定义为 DOAC 或 VKAs 摄入后 48 小时内发生的 ICH,无论入院时测量的国际标准化比值如何。
共纳入 748 例首次 ICH 患者,其中 108 例(14.4%)为 OAC 相关。具体而言,75 例(69.4%)ICH 发生在 VKA 上,33 例(30.6%)发生在 DOAC 上。口服抗凝相关脑出血(OAC-ICH)的发生率随时间保持稳定(p=0.226)。在 OAC-ICH 中,我们观察到 DOAC-ICH 的总体发生率增加(趋势检验 p<0.001),2020 年超过了 VKA-ICH(发病率比 4.71,95%置信区间(CI):1.22-33.54;p=0.022)。OAC-ICH 患者的 30 天病死率高于非 OAC-ICH 患者(48.1%比 34.1%;p=0.007)。
OAC-ICH 的发生率在时间上没有变化,但在整个研究期间,OAC-ICH 从主要与 VKA 相关转变为主要与 DOAC 相关。OAC-ICH 患者的死亡率高于非 OAC-ICH 患者。